Mirum Pharmaceuticals
NASDAQ: MIRMSan Diego, US · Incorporated in Delaware · 5 known investors
Find your way into Mirum Pharmaceuticals
295 people in our graph share verified history with the Mirum Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Bill Cilluffounlockedknows Chris Peetz · together at Stanford University Graduate School of Business (overlapped)
×9knows the team · via Stanford University Graduate School of Business
×2knows the team · via Frazierhealthcare
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
Founders & leadership
CP
Chris PeetzinCo-founder & Chief Executive OfficerCo-founder and CEO of Mirum Pharmaceuticals, a biopharmaceutical company developing therapies for rare diseases. He has held roles in finance, corporate development, marketing, and executive leadership at biopharmaceutical companies.
EB
Eric BjerkholtinExecutive
PR
Peter RadovichinExecutive
Board
PH
Patrick HeronBoard director
MG
Michael GreyBoard director
TW
Timothy WalbertBoard director
SR
Saira RamasastryBoard director
LC
Lon CardonBoard director
LF
Laurent FischerBoard director
WC
William C. FaireyBoard director
LB
Laura BregeBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$138.5M disclosed across 3 rounds · 2018–2026
▶$68.5MraisedJan 2026 · 2 investors · BiotechnologyRule 506(c)
▶$68.5MraisedJan 2026 · 2 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Michael GreyDirector
- Timothy WalbertDirector
- Saira RamasastryDirector
- Lon CardonDirector
- Laurent FischerDirector
- Eric BjerkholtExecutive Officer
- William C. FaireyDirector
- Christopher PeetzExecutive Officer, Director
- Peter RadovichExecutive Officer
- Laura BregeDirector
- Patrick HeronDirector
- Offering amount
- $68.5M
- Amount sold
- $68.5M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$10MraisedDec 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$10MraisedDec 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Patrick J. HeronDirector
- Pamela VigExecutive Officer
- Edwin Jonathan TuckerExecutive Officer
- Peter RadovichExecutive Officer
- Lara LongpreExecutive Officer
- Ian ClementsExecutive Officer
- Niall O'DonnellDirector
- Laurent FischerDirector
- Laura BregeDirector
- Christopher PeetzExecutive Officer, Director
- Tiba AynechiDirector
- Edward T. MathersDirector
- Michael G. GreyDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$60.1MraisedNov 2018 · 14 investors · PharmaceuticalsRule 506(b)
▶$60.1MraisedNov 2018 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chris PeetzDirector
- Patrick HeronDirector
- Susan DubeExecutive Officer
- Tiba AynechiDirector
- Ed MathersDirector
- Jonathan LeffDirector
- Michael GreyExecutive Officer, Director
- Offering amount
- $120.1M
- Amount sold
- $60.1M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Mirum Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Nextfinance.yahoo.com · Aug 2026
Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News - Simply Wall St Newssimplywall.st · Aug 2026
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript - AOLaol.com · Aug 2026
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline | Quiver Quantitativequiverquant.com · Aug 2026Frequently asked questions
- What does Mirum Pharmaceuticals do?
- Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
- Who founded Mirum Pharmaceuticals?
- Mirum Pharmaceuticals was founded by Chris Peetz.
- Who are Mirum Pharmaceuticals's investors?
- Mirum Pharmaceuticals's investors include Chiesi Ventures, Frazier Life Sciences, New Enterprise Associates (NEA), RiverVest Venture Partners, Norwest Venture Partners.
- How much funding has Mirum Pharmaceuticals raised?
- Mirum Pharmaceuticals has disclosed $138.5M raised across 3 rounds.
- Where is Mirum Pharmaceuticals headquartered?
- Mirum Pharmaceuticals is headquartered in San Diego, US.